P76.93 The Efficacy of Second-Line Osimertinib Plus Bevacizumab in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Abstract

Osimertinib has become the standard treatment for advanced non-small cell lung cancer patients with T790M mutation, who are resistant to EGFR tyrosine kinase inhibitors (EGFR TKIs). Moreover, Osimertinib has proven superior efficacy and safety over 1st-generation EGFR-TKIs in front-line setting, However, there is still insufficient evidence for the effect of Osimertinib combined with antiangiogenic therapy. Here, we reported the efficacy of Osimertinib plus Bevacizumab as second line treatment in advanced NSCLC patients in the real world setting.